Molecular Formula | C26H24Cl2N6O4 |
Molar Mass | 555.41 |
Density | 1.47±0.1 g/cm3(Predicted) |
Boling Point | 736.5±70.0 °C(Predicted) |
Solubility | DMSO |
pKa | 1.33±0.29(Predicted) |
Storage Condition | -20℃ |
MDL | MFCD30502893 |
In vitro study | HDM201 binds to the p53 binding site of the Mdm2 protein, disrupting the interaction between the two proteins, leading to activation of the p53 pathway. HDM201 is capable of inducing potent, p53-dependent cell cycle arrest and apoptosis in human p53 wild-type tumor cells. HDM201 is highly selective in a variety of cancer cell lines. |
In vivo study | HDM201 has good pharmacokinetic, pharmacodynamic properties and oral bioavailability in animal models. In a variety of human cancer xenograft models carrying wild-type p53, dosing with a variety of dosage schedules can cause rapid, sustained activation of p53-dependent pharmacodynamic biomarkers, resulting in tumor regression. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.8 ml | 9.002 ml | 18.005 ml |
5 mM | 0.36 ml | 1.8 ml | 3.601 ml |
10 mM | 0.18 ml | 0.9 ml | 1.8 ml |
5 mM | 0.036 ml | 0.18 ml | 0.36 ml |